Proteomics

Dataset Information

0

Clinical application of multiple reaction monitoring-mass spectrometry to HER2 measurements as a potential diagnostic tool for breast cancer therapy


ABSTRACT: Although the determination of HER2 expression in breast cancer would be of critical importance in the clinical management related to the selection of the patients who are expected to benefit from trastuzumab therapy, the conventional techniques have inherent limitations that disqualify their use as gold standards. Specifically, fluorescence in situ hybridization (FISH), which is mandatory for determining IHC 2+ cases, is time-consuming and economically inefficient. To address this shortcoming, we aimed to discriminate the equivocal HER2 status, which cannot be classified by the conventional method such as IHC, using a highly sensitive and quantitative MRM-MS assay. In order to assess the agreement between MRM-MS and IHC/FISH data, the quantitative data of a HER2 peptide was normalized by junctional adhesion molecule A (JAM1) levels, which is an epithelial cell-specific protein. The normalized HER2 levels differentiated the ambiguous IHC results of. In addition, the MRM-MS data distinguished HER2-negative breast cancer from the HER2-positive breast cancer that was expected to benefit from trastuzumab therapy. The newly developed HER2-targeted proteomic assay may provide a general strategy for complementing the limitations of conventional HER2-targeted therapeutic strategies.

ORGANISM(S): Homo Sapiens

SUBMITTER: Hyunsoo Kim  

PROVIDER: PXD017691 | panorama | Wed Mar 03 00:00:00 GMT 2021

REPOSITORIES: PanoramaPublic

altmetric image

Publications

Clinical Application of Multiple Reaction Monitoring-Mass Spectrometry to Human Epidermal Growth Factor Receptor 2 Measurements as a Potential Diagnostic Tool for Breast Cancer Therapy.

Do Misol M   Kim Hyunsoo H   Yeo Injoon I   Lee Jihyeon J   Park In Ae IA   Ryu Han Suk HS   Kim Youngsoo Y  

Clinical chemistry 20201001 10


<h4>Background</h4>Human epidermal growth factor receptor 2 (HER2) is often overexpressed in breast cancer and correlates with a worse prognosis. Thus, the accurate detection of HER2 is crucial for providing the appropriate measures for patients. However, the current techniques used to detect HER2 status, immunohistochemistry and fluorescence in situ hybridization (FISH), have limitations. Specifically, FISH, which is mandatory for arbitrating 2+ cases, is time-consuming and costly. To address t  ...[more]

Similar Datasets

2013-10-25 | E-GEOD-46350 | biostudies-arrayexpress
2013-10-25 | GSE46350 | GEO
2016-03-31 | E-GEOD-62327 | biostudies-arrayexpress
2023-09-01 | GSE231544 | GEO
2011-12-22 | E-GEOD-29431 | biostudies-arrayexpress
2011-12-22 | GSE29431 | GEO
2016-03-31 | GSE62327 | GEO
2021-12-31 | GSE149283 | GEO
2024-06-03 | GSE234519 | GEO
2022-07-16 | GSE47994 | GEO